Federated Hermes Inc. Has $109,000 Stock Position in Becton, Dickinson and Company $BDX

Federated Hermes Inc. cut its holdings in Becton, Dickinson and Company (NYSE:BDX) by 98.0% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 583 shares of the medical instruments supplier’s stock after selling 29,191 shares during the quarter. Federated Hermes Inc.’s holdings in Becton, Dickinson and Company were worth $109,000 at the end of the most recent reporting period.

Several other institutional investors have also recently bought and sold shares of BDX. SOA Wealth Advisors LLC. grew its holdings in shares of Becton, Dickinson and Company by 256.8% during the 3rd quarter. SOA Wealth Advisors LLC. now owns 132 shares of the medical instruments supplier’s stock valued at $25,000 after purchasing an additional 95 shares during the last quarter. Bell Investment Advisors Inc boosted its position in Becton, Dickinson and Company by 474.1% in the second quarter. Bell Investment Advisors Inc now owns 155 shares of the medical instruments supplier’s stock valued at $27,000 after buying an additional 128 shares in the last quarter. Grey Fox Wealth Advisors LLC bought a new stake in shares of Becton, Dickinson and Company during the third quarter worth $32,000. Bank of Jackson Hole Trust increased its holdings in shares of Becton, Dickinson and Company by 85.6% during the second quarter. Bank of Jackson Hole Trust now owns 206 shares of the medical instruments supplier’s stock worth $35,000 after buying an additional 95 shares in the last quarter. Finally, CVA Family Office LLC lifted its stake in shares of Becton, Dickinson and Company by 79.5% in the 2nd quarter. CVA Family Office LLC now owns 219 shares of the medical instruments supplier’s stock valued at $38,000 after acquiring an additional 97 shares during the last quarter. Institutional investors and hedge funds own 86.97% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the company. Royal Bank Of Canada restated a “sector perform” rating on shares of Becton, Dickinson and Company in a research report on Monday. Jefferies Financial Group upped their price objective on Becton, Dickinson and Company from $215.00 to $220.00 and gave the company a “buy” rating in a research note on Wednesday, December 10th. Piper Sandler lifted their target price on shares of Becton, Dickinson and Company from $190.00 to $205.00 and gave the stock a “neutral” rating in a research report on Wednesday, January 28th. Bank of America boosted their target price on shares of Becton, Dickinson and Company from $190.00 to $207.00 and gave the stock a “neutral” rating in a report on Monday, January 5th. Finally, Stifel Nicolaus raised their price target on shares of Becton, Dickinson and Company from $210.00 to $215.00 and gave the company a “buy” rating in a research note on Wednesday, January 7th. Five analysts have rated the stock with a Buy rating and eight have given a Hold rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $213.36.

Key Becton, Dickinson and Company News

Here are the key news stories impacting Becton, Dickinson and Company this week:

• Positive Sentiment: BDX beat on the quarter — adjusted EPS $2.91 (above estimates) and revenue $5.25B with margin expansion, showing operating resilience. BD Reports First Quarter Fiscal 2026 Financial Results
• Positive Sentiment: BD completed the combination of its Biosciences & Diagnostic Solutions business with Waters Corporation — a strategic divestiture that crystallizes a leaner “New BD.” BD Completes Combination with Waters
• Positive Sentiment: Management announced a $4.0B cash deployment plan tied to the Waters transaction (capital return / balance‑sheet actions), which can be supportive for EPS and shareholder value over time. BD Outlines EPS Guidance and $4B Cash Deployment
• Neutral Sentiment: Top‑line growth was modest (reported revenue +1.6% YoY) and the company affirmed revenue growth guidance for the year — positive for stability but not a catalyst for re-rating. Q1 Financial Results
• Neutral Sentiment: Some insiders placed bullish option bets recently (small dollar amount reported), a signal of confidence from insiders but limited scale. Insiders Placed Bullish Bets
• Negative Sentiment: Management set FY‑2026 adjusted EPS guidance for New BD at $12.35–$12.65 — materially below prior consensus (~$14.8), reflecting the sale/spin and lowering the company’s standalone earnings outlook; that guidance reset is the primary negative catalyst. Reuters: Becton Dickinson cuts annual profit forecast
• Negative Sentiment: Market reaction: shares sold off after the print/guidance reset — analysts flagged the guidance shortfall vs. consensus and some maintained cautious ratings (e.g., Hold). Increased volume suggests the guidance-driven repricing is broad-based. Zacks: Stock Dips Despite Earnings Beat

Becton, Dickinson and Company Trading Down 1.3%

BDX opened at $207.31 on Tuesday. Becton, Dickinson and Company has a twelve month low of $162.29 and a twelve month high of $235.34. The company has a fifty day moving average of $200.14 and a 200-day moving average of $192.53. The stock has a market cap of $59.06 billion, a PE ratio of 35.56, a price-to-earnings-growth ratio of 2.32 and a beta of 0.25. The company has a quick ratio of 0.64, a current ratio of 1.11 and a debt-to-equity ratio of 0.69.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings results on Monday, February 9th. The medical instruments supplier reported $2.91 EPS for the quarter, beating analysts’ consensus estimates of $2.81 by $0.10. Becton, Dickinson and Company had a net margin of 7.68% and a return on equity of 16.42%. The business had revenue of $5.25 billion for the quarter, compared to analysts’ expectations of $5.15 billion. During the same quarter in the prior year, the firm posted $3.43 earnings per share. The business’s quarterly revenue was up 1.6% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 12.350-12.650 EPS. On average, sell-side analysts predict that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 31st. Investors of record on Tuesday, March 10th will be paid a dividend of $1.05 per share. The ex-dividend date of this dividend is Tuesday, March 10th. This represents a $4.20 annualized dividend and a yield of 2.0%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is currently 72.04%.

Becton, Dickinson and Company declared that its Board of Directors has authorized a stock repurchase plan on Tuesday, January 27th that authorizes the company to buyback $10.00 million in outstanding shares. This buyback authorization authorizes the medical instruments supplier to reacquire up to 0% of its stock through open market purchases. Stock buyback plans are usually a sign that the company’s management believes its shares are undervalued.

Insider Transactions at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 1,610 shares of the stock in a transaction that occurred on Thursday, January 15th. The stock was sold at an average price of $207.46, for a total transaction of $334,010.60. Following the transaction, the executive vice president directly owned 12,095 shares in the company, valued at approximately $2,509,228.70. This represents a 11.75% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders sold 2,463 shares of company stock valued at $501,530 over the last quarter. 0.40% of the stock is currently owned by insiders.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.